Travis Perkins PLC
23 March 2007
TRAVIS PERKINS PLC
Director/PDMR Shareholding
The Board of Travis Perkins plc (the 'Company') was informed yesterday in
accordance with DTR 3.1.4R(1)(a) that on 22 March 2007 the Executive Directors
and members of the Company's Executive Committee were granted options under the
Travis Perkins 2001 Executive Share Option Scheme over ordinary shares of the
Company at an exercise price of 1970p. The exercise period is from 22 March 2010
to 21 March 2017. The number of shares held under option by the Executive
Directors and members of the Company's Executive Committee are set out below:
Director Number of shares Total number of shares
under this Grant under option following this grant
Geoff Cooper 50,761 161,754
Paul Hampden Smith 31,091 274,724
John Carter 31,091 192,873
Andrew Pike 12,944 71,867
Carol Kavanagh 17,131 36,049
Martin Meech 19,035 49,665
Jeremy Bird 17,512 45,633
In case of queries, please contact Anthony Kemp, 01604 752424
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.